论文部分内容阅读
目的观察卵巢癌患者自体细胞因子诱导杀伤细胞治疗前后患者外周血淋巴细胞亚群的变化,为综合评价临床应用CIK细胞疗法治疗卵巢癌的效果提供依据。方法2004-2005采集中国医科大学附属第一医院5例卵巢癌患者的外周血单个核细胞,经多种细胞因子诱导制成CIK细胞,回输前及回输后取患者外周血,流式细胞仪测定外周血淋巴细胞亚群的变化。结果诱导培养后,CD3+/CD56+效应细胞的比例明显升高;CIK细胞回输后患者外周血CD3+、CD3+/CD8+、CD3+/CD56+阳性淋巴细胞亚群的比例明显升高。结论CIK细胞疗法可以提高卵巢癌患者的细胞免疫功能,提高对肿瘤细胞的杀伤作用。
Objective To observe the changes of peripheral blood lymphocyte subsets in patients with ovarian cancer before and after autologous cytokine-induced killer cells treatment, and to provide a basis for comprehensive evaluation of clinical application of CIK cell therapy in treating ovarian cancer. Methods From 2004 to 2005, peripheral blood mononuclear cells from 5 ovarian cancer patients in the First Affiliated Hospital of China Medical University were collected and CIK cells were induced by various cytokines. Peripheral blood mononuclear cells were collected before and after transfusion. Flow cytometry Measurement of peripheral blood lymphocyte subsets changes. Results After induction, the proportion of CD3 + / CD56 + effector cells was significantly increased. The percentage of CD3 +, CD3 + / CD8 + and CD3 + / CD56 + positive lymphocytes in peripheral blood of CIK cells was significantly increased after CIK cells were transfused. Conclusion CIK cell therapy can improve the cellular immune function of ovarian cancer patients and increase the killing effect on tumor cells.